NASDAQ:ADXS - Advaxis, Inc.
$0.42
 $0.01
+3.62%
2:10PM EDT
2019-02-15
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ADXS     avg for
industry  
  avg for
sector  
42 stocks weight:  17. 84   0. 00   0. 00  
42 stocks rank:  3. 73 K 1. 86 K 1. 09 K
# analyst opinions:  2. 00   14. 92   14. 43  
mean recommendation:  2. 70   1. 91   1. 93  

quick ratio:  1. 93   5. 37   1. 81  
current ratio:  2. 21   5. 69   2. 19  

target price low:  0. 25   88. 97   117. 82  
target price avg:  0. 30   115. 19   141. 96  
target price high:  0. 64   143. 40   163. 16  
1-yr high:  2. 59   124. 30   142. 77  
last close:  0. 41   101. 85   127. 84  
50-day avg:  0. 33   98. 27   122. 46  
200-day avg:  1. 00   99. 72   122. 70  
1-yr low:  0. 19   78. 19   100. 16  
volume:  404. 53 K 2. 38 M 4. 64 M
50-day avg volume:  914. 27 K 3. 31 M 4. 94 M
200-day avg volume:  797. 59 K 3. 23 M 4. 28 M

1-day return:  2. 50 % 0. 22 % 0. 48 %
this week return:  7. 89 % 1. 77 % 2. 01 %
12-wk return:  -11. 26 % 6. 56 % 3. 33 %
52-wk return:  -85. 87 % -2. 23 % 14. 35 %

enterprise value (EV):  -17. 51 M 55. 17 B 104. 51 B
market cap:  28. 79 M 49. 01 B 96. 46 B
EBITDA:  -67. 43 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 26   -91. 79   2. 29  
enterprise/revenue (EV/R):  -2. 89   29. 84   23. 39  
total revenue:  6. 06 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -66. 52 M 2. 37 B 3. 58 B

shares outstanding:  69. 70 M 607. 99 M 1. 22 B
shares:  65. 40 M 605. 53 M 1. 15 B
shares short:  2. 47 M 11. 62 M 12. 55 M
shares short prior month:  2. 23 M 11. 95 M 13. 44 M
short ratio:  1. 94   4. 82   3. 10  
short % of float:  3. 59 % 6. 19 % 2. 82 %
total cash/share:  0. 63   12. 02   11. 46  
total cash:  44. 14 M 7. 41 B 7. 37 B
free cash flow:  -30. 80 M 95. 99 M 2. 04 B
operating cash flow:  -62. 13 M 164. 74 M 3. 04 B

book value:  0. 35   14. 43   28. 26  
price/book:  1. 18   -1. 57   -2. 97  
gross profits:  6. 06 M 8. 28 B 18. 09 B
operating margins:  -1136. 93 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  100. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  57. 89 % --- ---
1-yr mean volatility:  -0. 45 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 29   3. 03   4. 09  
forward EPS:  -0. 43   4. 33   6. 99  
P/E:  -0. 32   6. 11   26. 91  
forward P/E:  -0. 93   8. 38   10. 48  
PE/G:  0. 01   0. 37   5. 61  
growth:  -36. 00 % 683. 72 % 104. 79 %
earnings high:  -0. 22   1. 27   1. 66  
earnings avg:  -0. 25   1. 01   1. 53  
earnings low:  -0. 28   0. 76   1. 40  
revenue high:  2. 00 M 2. 86 B 11. 19 B
revenue avg:  1000. 00 K 2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -55. 27 % -3. 27 % 3. 81 %
return on equity:  -169. 87 % 107. 48 % 27. 82 %
revenue growth:  -36. 00 % 648. 36 % 97. 70 %
revenue/share:  0. 12   14. 68   59. 83  

beta (1yr vs S&P500):  1. 30   1. 21   0. 93  
sharpe (1yr):  -0. 92   0. 06   0. 98  

held % insiders:  6. 30 % 6. 46 % 3. 21 %
held % institutions:  24. 33 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ADXS
.        + 0 =             0 :: INITIAL WEIGHT
.   + 177.28 =        177.28 :: inverse volume-to-price addition
.  + 160.634 =       337.914 :: spline projection addition
.  - 244.992 =        92.921 :: poor performance penalty
.    x 0.474 =        44.024 :: one-year gains+dividend factor
.    x 7.576 =       333.504 :: 13 weeks' performance factor
.    x 1.492 =       497.752 :: industry recommendation factor
.    x 1.315 =       654.426 :: symbol recommendation factor
.    x 0.994 =       650.809 :: return on assets factor
.    x 0.983 =       639.753 :: return on equity factor
.    x 0.996 =        637.45 :: revenue growth factor
.    x 2.387 =      1521.884 :: current ratio factor
.    x 1.427 =      2172.061 :: quick ratio factor
.    x 1.231 =      2673.897 :: short ratio factor
.    x 2.012 =       5379.48 :: price-to-book factor
.    x 5.657 =     30433.784 :: EBITDA multiple factor
.    x 1.205 =     36676.137 :: 5-day avg > 50-day avg
.    x 2.175 =     79788.316 :: P/E weight
.    x 2.209 =    176249.127 :: PE/G factor
.    x 1.434 =    252745.509 :: beta factor
.     x 0.92 =    232612.361 :: sharpe factor
.    x 0.938 =    218081.182 :: target low factor
.    x 0.908 =    198059.639 :: target mean factor
.    x 1.074 =     212784.56 :: target high factor
.    x 1.066 =    226745.952 :: industry 12-weeks return
.    x 0.997 =    226171.457 :: overall "drift" factor
.    x 0.421 =     95230.083 :: largest single-day jump factor
.     x 0.06 =      5678.598 :: low price factor
.      x 1.0 =      5678.979 :: factor hist industry gain for week 06
.   cubeRoot =        17.841 :: reduced for readability
.                     17.841 :: FINAL WEIGHT for NASDAQ:ADXS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org